Thalamic or hypothalamic astrocytoma
Research & Innovation
Dana-Farber/Children's Hospital Cancer Center is a member of the Pediatric Oncology Therapeutic Experimental Investigators Consortium (POETIC), a collaborative clinical research group offering experimental therapies to patients with relapsed (returning) or refractory (resistant to treatment) disease. It is also the New England Phase I Center of the Children's Oncology Group and a member of the Department of Defense Neurofibromatosis Clinical Trial Consortium.
We are home to the only dedicated pediatric low-grade glioma program, the Pediatric Low-Grade Astrocytoma (PLGA) Research Program. In addition to the discovery of a number of novel targets, this program has initiated a number of phase II protocols using molecular inhibitors for children with progressive/recurrent low-grade glioma.
Through the PLGA Research Program, we have pioneered strategies for analyzing the genetic and molecular characteristics of pediatric low-grade astrocytomas. In collaboration with the Broad Institute of Harvard and MIT, we have made strides toward a better understanding of these conditions. Through the program, we’ve also established a patient registry and multiple international research projects.
|Find out more about the innovative clinical trials available at the Dana-Farber/Children’s Hospital Cancer Center.|
Reviewed by Mark Kieran, MD, PhD
© Children’s Hospital Boston, 2010